AR094577A1 - Composiciones para el tratamiento de cáncer, preparación y usos de las mismas - Google Patents
Composiciones para el tratamiento de cáncer, preparación y usos de las mismasInfo
- Publication number
- AR094577A1 AR094577A1 ARP140100222A ARP140100222A AR094577A1 AR 094577 A1 AR094577 A1 AR 094577A1 AR P140100222 A ARP140100222 A AR P140100222A AR P140100222 A ARP140100222 A AR P140100222A AR 094577 A1 AR094577 A1 AR 094577A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor
- volume
- composition
- cancer
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1089—Electrons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una composición caracterizada porque induce en un sujeto humano que posee un tumor (i) la destrucción de más de 30% de las células cancerosas en un volumen del tumor o (ii) al menos más de 20% de reducción del tamaño del tumor cuando el volumen (Vc) de dicha composición ocupa entre 2 y 50% del volumen del tumor (Vt) y cuando el tumor es expuesto a radiaciones ionizantes, en tanto la composición comprende nanopartículas inorgánicas que tienen un volumen (Vin) que tienen una densidad de electrones, al menos, 5 veces la densidad de electrones del volumen correspondiente 1 (Vw1) de agua. Reivindicación 5: La composición de acuerdo a cualquiera de las reivindicaciones 1 a 4, caracterizada porque el material inorgánico de la nanopartícula posee una densidad teórica (volumétrica) de por lo menos 7 y un número atómico efectivo (Zₑᶠᶠ) de por lo menos 25. Reivindicación 6: La composición de acuerdo a la reivindicación 5, caracterizada porque el material inorgánico se selecciona entre un óxido, un metal, un sulfuro o cualquier mezcla de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305087 | 2013-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094577A1 true AR094577A1 (es) | 2015-08-12 |
Family
ID=47710064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100222A AR094577A1 (es) | 2013-01-25 | 2014-01-24 | Composiciones para el tratamiento de cáncer, preparación y usos de las mismas |
Country Status (23)
Country | Link |
---|---|
US (4) | US10098952B2 (es) |
EP (1) | EP2948179B1 (es) |
JP (2) | JP6619231B2 (es) |
KR (2) | KR102225239B1 (es) |
CN (1) | CN105120897B (es) |
AR (1) | AR094577A1 (es) |
AU (1) | AU2014209899B2 (es) |
BR (1) | BR112015017490A2 (es) |
CA (2) | CA2897362C (es) |
CY (1) | CY1121838T1 (es) |
EA (1) | EA034242B1 (es) |
HK (1) | HK1216609A1 (es) |
IL (1) | IL239767B (es) |
MA (1) | MA38318A1 (es) |
MX (1) | MX369664B (es) |
PL (1) | PL2948179T3 (es) |
RS (1) | RS59042B1 (es) |
SG (1) | SG11201505277VA (es) |
SI (1) | SI2948179T1 (es) |
TW (1) | TW201442726A (es) |
UA (1) | UA116007C2 (es) |
WO (1) | WO2014114732A1 (es) |
ZA (1) | ZA201505510B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857260C (en) | 2011-12-16 | 2019-10-15 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
KR102225239B1 (ko) | 2013-01-25 | 2021-03-09 | 나노비오?笭? | 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물 |
EP2886128A1 (en) * | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
TW201705977A (zh) | 2015-05-28 | 2017-02-16 | 奈諾生技公司 | 作為治療疫苗之奈米顆粒 |
US11278723B2 (en) * | 2016-12-21 | 2022-03-22 | Nanobiotix S.A. | Nanoparticles for use for treating a neuronal disorder |
JP2020504732A (ja) * | 2016-12-21 | 2020-02-13 | ナノビオティックスNanobiotix | 脳活動の増強に使用するための、又はストレスの処置に使用するためのナノ粒子 |
EP3424533A1 (en) * | 2017-07-05 | 2019-01-09 | Nh Theraguix | Methods for treating tumors |
EP3654976A1 (en) * | 2017-07-21 | 2020-05-27 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
JP2022540652A (ja) | 2019-07-12 | 2022-09-16 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 分裂期キナーゼ阻害剤と免疫チェックポイント阻害剤との同時送達のための治療用構築物 |
US20220249389A1 (en) * | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
WO2021011496A1 (en) * | 2019-07-12 | 2021-01-21 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
WO2021215952A1 (ru) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Способ получения частиц бактериофагов семейства levivirus |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
BR0115127A (pt) * | 2000-11-20 | 2004-02-17 | Oncolytics Biotech Inc | Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor |
US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
FR2884149B1 (fr) * | 2005-04-12 | 2007-06-08 | Henri Mehier | Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal |
EP2130553A1 (en) * | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
US8395131B2 (en) * | 2009-06-20 | 2013-03-12 | Xiaodong Wu | Method for three dimensional (3D) lattice radiotherapy |
EP2275137A1 (en) * | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
EP2555800B1 (en) | 2010-04-05 | 2018-03-21 | Nanospectra Biosciences, Inc. | Enhancement of radiation therapy by targeted high-z nanoparticles |
CA2857260C (en) * | 2011-12-16 | 2019-10-15 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
KR102225239B1 (ko) | 2013-01-25 | 2021-03-09 | 나노비오?笭? | 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물 |
-
2014
- 2014-01-24 KR KR1020157022940A patent/KR102225239B1/ko active IP Right Grant
- 2014-01-24 SG SG11201505277VA patent/SG11201505277VA/en unknown
- 2014-01-24 WO PCT/EP2014/051367 patent/WO2014114732A1/en active Application Filing
- 2014-01-24 EA EA201591378A patent/EA034242B1/ru not_active IP Right Cessation
- 2014-01-24 UA UAA201508289A patent/UA116007C2/uk unknown
- 2014-01-24 JP JP2015554149A patent/JP6619231B2/ja active Active
- 2014-01-24 SI SI201431254T patent/SI2948179T1/sl unknown
- 2014-01-24 MA MA38318A patent/MA38318A1/fr unknown
- 2014-01-24 AU AU2014209899A patent/AU2014209899B2/en active Active
- 2014-01-24 BR BR112015017490A patent/BR112015017490A2/pt not_active Application Discontinuation
- 2014-01-24 EP EP14701965.7A patent/EP2948179B1/en active Active
- 2014-01-24 AR ARP140100222A patent/AR094577A1/es unknown
- 2014-01-24 CA CA2897362A patent/CA2897362C/en active Active
- 2014-01-24 US US14/762,971 patent/US10098952B2/en active Active
- 2014-01-24 KR KR1020217006350A patent/KR102385193B1/ko active IP Right Grant
- 2014-01-24 CN CN201480006025.0A patent/CN105120897B/zh active Active
- 2014-01-24 CA CA3179586A patent/CA3179586A1/en active Pending
- 2014-01-24 TW TW103102786A patent/TW201442726A/zh unknown
- 2014-01-24 PL PL14701965T patent/PL2948179T3/pl unknown
- 2014-01-24 RS RS20190848A patent/RS59042B1/sr unknown
- 2014-01-24 MX MX2015009409A patent/MX369664B/es active IP Right Grant
-
2015
- 2015-07-02 IL IL239767A patent/IL239767B/en active IP Right Grant
- 2015-07-31 ZA ZA2015/05510A patent/ZA201505510B/en unknown
-
2016
- 2016-04-19 HK HK16104483.8A patent/HK1216609A1/zh unknown
-
2018
- 2018-06-06 JP JP2018108835A patent/JP2018168162A/ja active Pending
- 2018-09-13 US US16/129,851 patent/US11020480B2/en active Active
-
2019
- 2019-07-17 CY CY20191100762T patent/CY1121838T1/el unknown
-
2021
- 2021-05-27 US US17/331,674 patent/US11819548B2/en active Active
-
2023
- 2023-11-16 US US18/510,716 patent/US20240100163A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094577A1 (es) | Composiciones para el tratamiento de cáncer, preparación y usos de las mismas | |
CY1121078T1 (el) | Ανοργανα νανοσωματιδια υψηλης πυκνοτητας για καταστροφη κυτταρων in-vivo | |
CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
NI201600022A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
CY1118600T1 (el) | Μεταλλικα νανοσωματιδια, παρασκευη και χρησεις αυτων | |
BR112017000800A8 (pt) | Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico | |
WO2014194435A3 (en) | Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component. | |
CL2015000311A1 (es) | El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades. | |
CL2015002433A1 (es) | Imidazopiridazinas sustituidas | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
WO2014182789A3 (en) | Radiomitigating pharmaceutical formulations | |
BR102015006886B8 (pt) | Composição tópicas que compreendem 4-hexilresorcinol e pós e uso | |
AR093220A1 (es) | Dispositivo de irradiacion de una composicion tipo pasta | |
CU24650B1 (es) | Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer | |
GB2562661B (en) | Oil palm phenolics composition for the protection of human organs, cells and tissues against the injurious effects of exposure to ionizing radiation | |
ITUB20160828A1 (it) | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro | |
HRP20191272T1 (hr) | Pripravci koji sadrže nano čestice hafnium (iv) oksida ili renij (iv) oksida u kombinaciji s ionizirajućim zračenjem za liječenje raka | |
CO2017002490A2 (es) | Composición cosmética reductiva de aplicación tópica que contiene queratina y azufre | |
Kumar et al. | K-SHELL AND L-SHELL IONIZATION CROSS SECTIONS OF SILVER ATOM BY ELECTRON IMPACTS | |
TH158872B (th) | องค์ประกอบอนุภาคนาโนอนินทรีย์ร่วมกับรังสีไอออไนซ์สำหรับการรักษามะเร็ง | |
AR113848A1 (es) | Formas de dosificación que contienen un inhibidor calicreína de plasma | |
AR114814A1 (es) | Composición antioxidante | |
Nurul | Best Reviewers for the Year 2017 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |